收购

Search documents
去年净利润未过亿元的迈普医学,欲收购未盈利企业,股价复牌后大跌
Di Yi Cai Jing· 2025-06-06 07:42
Core Viewpoint - Maipu Medical announced a restructuring plan to acquire 100% of Yijie Medical, which is expected to expand its product offerings in the neurosurgery field, despite concerns over potential financial impacts due to Yijie Medical's current losses [2][3]. Group 1: Company Overview - Maipu Medical is the only company in China's neurosurgery field that offers a comprehensive range of implantable medical devices, including artificial dura mater patches and absorbable hemostatic agents [2]. - Yijie Medical specializes in the research, design, and sales of vascular interventional medical devices for neurology, with products such as neurointerventional catheters and balloon dilation catheters [2]. Group 2: Financial Performance - In 2024, Maipu Medical reported a net profit of 78.85 million yuan, showing a growth trend from 2022 to 2024 [3]. - Yijie Medical is projected to incur net losses of 29.51 million yuan in 2023 and 26.16 million yuan in 2024, raising concerns about the impact of the acquisition on Maipu Medical's financial performance [3]. Group 3: Market and Competitive Landscape - The acquisition is seen as a strategic move to enhance Maipu Medical's product categories by integrating biocomposite material technology into the interventional field [2]. - There are concerns regarding market competition, as existing products in the neurointerventional medical device sector maintain high market shares, and potential new products could disrupt the market [3].
苏垦农发拟1.78亿元增持金太阳粮油 资产负债率48.96%累计分红25.82亿元
Chang Jiang Shang Bao· 2025-06-05 17:08
据了解,金太阳粮油前身为江苏金太阳油脂有限责任公司,成立于1996年,并于2015年整体变更为股份 公司,更名为"金太阳粮油股份有限公司"。2016年,金太阳粮油股票在新三板挂牌。 近几年,金太阳粮油业绩波动不小。财务数据显示,2023年及2024年,金太阳粮油营业收入分别为 25.08亿元、22.83亿元,同比分别下降23.72%、9%;归属于挂牌公司股东的净利润分别为540.42万元、 4794.94万元,同比分别变动-92.79%、787.27%。 对此,苏垦农发在公告中解释称,食用油领域是高度竞争的行业,2023年受原材料价格波动影响,金太 阳粮油经营业绩出现大幅下滑,2024年以来市场行情已有所好转,但未来市场环境仍存在较大不确定 性。 长江商报奔腾新闻记者徐阳 农业公司苏垦农发(601952)(601952.SH)继续增持金太阳(300606)粮油股份有限公司(以下简称"金太 阳粮油")股份。 6月4日晚,苏垦农发公告称,公司拟使用自有资金,以现金为对价,通过特定事项协议转让方式受让金 太阳粮油2300万股(占比28.75%)无限售条件股份,交易金额为1.78亿元。 苏垦农发表示,本次交易是公司基 ...
*ST亚振: 要约收购报告书
Zheng Quan Zhi Xing· 2025-06-05 13:36
| 亚振家居股份有限公司 | | | | --- | --- | --- | | 上市公司: | 亚振家居股份有限公司 | | | 上市地点: | 上海证券交易所 | | | 股票简称: | *ST 亚振 | | | 股票代码: | 603389.SH | | | 收购人: | 吴涛 | | | 住所: | 济南市市中区**** | | | 收购人之一致行动人: | 范伟浩 | | | 住所: | 北京市昌平区**** | | | | 收购方财务顾问 | | | 签署日期:二〇二五年六月 | | | | 亚振家居股份有限公司 | | 要约收购报告书 | 亚振家居股份有限公司 要约收购报告书 特别提示 本部分所述的词语或简称与本报告书释义部分所定义的词语或简称具有相 同的含义。 一、本次要约收购的收购人为自然人吴涛先生。本次要约收购主要基于收购 人及其一致行动人对上市公司价值及未来发展前景的认可,吴涛先生拟通过本次 要约收购增加对上市公司的持股比例,进一步巩固对*ST 亚振的控制权。 二、2025 年 4 月 17 日,亚振投资及高伟先生、户美云女士、高银楠女士与 吴涛先生签署了《股份转让协议一》,约定亚振投资 ...
*ST亚振: 江苏泰和律师事务所关于亚振家居要约收购报告书之法律意见书
Zheng Quan Zhi Xing· 2025-06-05 13:25
法律意见书 江苏泰和律师事务所 关于 《亚振家居股份有限公司要约收购报告书》 之 法律意见书 法律意见书 法律意见书 江苏泰和律师事务所 关于《亚振家居股份有限公司要约收购报告书》之 法律意见书 致:吴涛先生 江苏泰和律师事务所接受收购人的委托,作为本次要约收购的专项法律顾 问,根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司收 购管理办法》及《公开发行证券的公司信息披露内容与格式准则第 17 号——要 约收购报告书》等现行法律、法规、规范性文件的规定,按照律师行业公认的 业务标准、道德规范和勤勉尽责精神,就收购人为本次要约收购编制的《要约 收购报告书》的有关事项,出具本法律意见书。 法律意见书 一、释义 | 本法律意见书中,除非上下文另有所指,下列用语的释义如下: | | | | --- | --- | --- | | 收购人 | 指 吴涛先生 | | | 一致行动人 | 指 | 范伟浩先生,即吴涛先生之一致行动人 | | 上 市 公 司 / 亚 振 家 居 /*ST | | | | 指 | 亚振家居股份有限公司 | | | 亚振 | | | | 上市公司原控股股东/亚 | | | | 指 | ...
*ST亚振: 华泰联合证券有限责任公司关于吴涛要约收购亚振家居之财务顾问报告
Zheng Quan Zhi Xing· 2025-06-05 13:14
华泰联合证券有限责任公司 关于 吴涛 要约收购 亚振家居股份有限公司 之 财务顾问报告 二〇二五年六月 财务顾问声明 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司收购 管理办法》及《公开发行证券的公司信息披露内容与格式准则第 17 号——要约 收购报告书》等法律法规和规范性文件的规定,华泰联合证券有限责任公司(以 下简称"本财务顾问")按照行业公认的业务标准、道德规范,本着诚实信用、 勤勉尽责的精神,对本次收购的相关情况和资料进行了核查,对收购人出具的《亚 振家居股份有限公司要约收购报告书》所披露的内容出具财务顾问报告。 为此,本财务顾问特作出以下声明: 所提供的资料均为真实、准确、完整的原始书面资料或副本资料,副本资料或复 印件与其原始资料或原件一致,所有文件的签名、印章均是真实的;所有文件和 材料不存在虚假记载、误导性陈述或重大遗漏,并对所提供信息的真实性、准确 性和完整性承担法律责任。 和验证,未发现虚假记载、误导性陈述或者重大遗漏,并对此承担相应的责任。 《要约收购报告书》的内容不存在实质性差异。 并同意出具此专业意见。 措施,严格执行风险控制和内部隔离制度,不存在内幕交易、操纵市场 ...
周立功,被收购
半导体芯闻· 2025-06-05 10:04
Core Viewpoint - The company, Nanjing Shangluo Electronics Co., Ltd., has signed an investment intention agreement to acquire a controlling stake in Guangzhou Ligong Technology Co., Ltd., which is a distributor of electronic components, enhancing the company's competitiveness and sales scale [1][14]. Agreement Signing Situation - The company has entered into an investment intention agreement with major shareholders of Ligong Technology, aiming to purchase part of the equity through cash to achieve control over the target company [6][7]. Basic Information of the Target Company - Guangzhou Ligong Technology Co., Ltd. was established on February 5, 1999, with a registered capital of 320 million RMB. The company specializes in wholesale of electronic components and related services [8][9]. Main Content of the Intention Agreement - The agreement outlines that the company intends to acquire equity from existing shareholders to gain control. The final transaction price will be determined based on due diligence and mutual agreement [12][13]. Impact of the Agreement on the Company - The acquisition aligns with the company's strategic focus on distribution, allowing for industry chain extension and improvement in overall competitiveness, sales scale, and profitability [14][15].
浙江龙盛50亿收购全球染料巨头 十年股权交易纠纷迎来终局?
Zhong Guo Jing Ying Bao· 2025-06-05 09:58
Core Viewpoint - Zhejiang Longsheng plans to acquire a 37.57% stake in DyStar from KIRI for $697 million, which will make DyStar a wholly-owned subsidiary, potentially ending a nearly decade-long legal dispute with KIRI [2][3][4] Group 1: Acquisition Details - The acquisition price of $697 million (approximately 5.02 billion RMB) is significantly higher than previous valuations, reflecting the rising value of DyStar's shares over the years [2][3] - DyStar is a leading provider of high-end dye and chemical solutions, and the acquisition is seen as a strategic move to consolidate resources and eliminate potential shareholder disputes [4][5] Group 2: Historical Context - DyStar faced bankruptcy in 2010 and was acquired by KIRI for €40 million, while Zhejiang Longsheng initially invested €22 million in KIRI's convertible bonds, later converting to a 62.43% stake in DyStar [3][4] - A series of legal battles began in 2015 when KIRI accused Zhejiang Longsheng of oppressing minority shareholders, leading to multiple court rulings that increased the valuation of the stake [3][4] Group 3: Financial Performance - Zhejiang Longsheng's revenue and profit have fluctuated significantly from 2020 to 2024, with a notable decline in 2023 due to intense market competition and price pressures [6][7] - The company reported a revenue of 156.05 billion RMB in 2020, down 26.96% year-on-year, and a net profit of 41.76 billion RMB, down 16.86% [6] - In 2024, the company anticipates a rebound with projected revenue of 158.84 billion RMB, a slight increase of 3.80%, and a net profit of 20.30 billion RMB, reflecting a growth of over 30% [7]
紫金矿业(601899):2025年中期策略会速递:有成长性、稳健经营的铜金龙头矿企
HTSC· 2025-06-05 09:53
Investment Rating - The report maintains a "Buy" rating for the company [1][5][8]. Core Views - The company is characterized as a growth-oriented and stable operator in the copper mining sector, with recent discussions on key events such as the spin-off listing in Hong Kong, acquisition of藏格矿业, and the temporary shutdown of卡莫阿铜矿 [1]. - The spin-off of the subsidiary, 紫金黄金国际, aims to create an independent financing platform and enhance the valuation of its gold assets, although the completion of this spin-off remains uncertain [2]. - The acquisition of control over藏格矿业 has been completed, increasing the company's stake to 26.18%, which is expected to facilitate better management and integration of operations [3]. - The卡莫阿-卡库拉铜矿 has experienced a temporary shutdown due to seismic activity, but the impact on production for 2025 is expected to be limited, with a projected copper output of 520,000 to 580,000 tons [4]. Financial Projections - The report forecasts net profits for the company to be RMB 44 billion, RMB 46.5 billion, and RMB 51.8 billion for the years 2025, 2026, and 2027 respectively [5][7]. - Revenue projections for the company are set at RMB 345.3 billion, RMB 368.3 billion, and RMB 390.6 billion for the years 2025, 2026, and 2027 respectively, indicating a growth rate of 13.73%, 6.67%, and 6.04% [7][18]. - The report provides a detailed breakdown of financial ratios, including an expected EPS of RMB 1.52 for 2025 and a projected ROE of 26.1% [7][18]. Valuation Metrics - The report maintains a target price of RMB 22.49 and HKD 21.73 for the company's A/H shares, based on a cautious valuation approach [5][8]. - The report notes that the average PE ratios for comparable companies in the copper, gold, and zinc sectors are 11, 20, and 14 respectively for 2025 [5][13].
易明医药6.6亿易主姚劲波暂收涨停 单品贡献72%营收利润3000万待观察
Chang Jiang Shang Bao· 2025-06-04 23:14
Core Viewpoint - Yao Jinbo, known for founding 58.com, is set to become the actual controller of A-share company Yiming Pharmaceutical through a significant equity acquisition, raising questions about the company's growth potential and risks associated with its reliance on a single product [3][5][13]. Group 1: Acquisition Details - Yiming Pharmaceutical's major shareholder, Gao Fan, signed a share transfer agreement to sell 23% of the company's equity to Beijing Fuhao, controlled by Yao Jinbo, for 662 million yuan, at a price of 15.10 yuan per share, representing a 24% premium over the last closing price before the announcement [3][10][12]. - Following the announcement, Yiming Pharmaceutical's stock price hit the daily limit, closing at 13.40 yuan per share [10]. - The transaction will result in a change of control, with Beijing Fuhao becoming the new controlling shareholder and Yao Jinbo the actual controller [9][12]. Group 2: Financial Performance and Risks - Yiming Pharmaceutical's profitability has been inconsistent, with projected net profits of 44 million yuan, 15 million yuan, and 46 million yuan from 2022 to 2024, and a significant decline of over 30% in Q1 2024 compared to the previous year [3][14]. - The company heavily relies on a single product, Miglitol tablets, which accounted for 72% of its revenue in 2024, raising concerns about the sustainability of its business model [3][14]. - The company has established a performance guarantee agreement, with Gao Fan committing to ensure that the company's revenue does not fall below 600 million yuan and net profit does not drop below 30 million yuan over the next three years [4][16].
“五问”菲林格尔蹊跷易主交易
Shang Hai Zheng Quan Bao· 2025-06-04 19:15
昨日,停牌前股价提前涨停的菲林格尔发布了控制权拟变更的提示性公告并复牌。 本次交易可分为两部分。一,安吉以清科技合伙企业(有限合伙)(下称"安吉以清")及实控人金亚伟 拟受让菲林格尔实控人丁福如及其一致行动人的股份合计25%,成为上市公司新控股股东和实控人。而 丁福如方仍持有菲林格尔19.56%股权,但承诺"放弃争夺控制权"。二,菲林格尔单一第一大股东菲林格 尔控股拟将所持27.22%股权协议转让给陕国投·乐盈267号信托、渤源达朗基金、和融联基金(简称"三 只信托及私募产品"),实现完全退出。 然而,此次易主交易结构之复杂、股权安排之巧妙,折射出背后诸多蹊跷之处。 自称相互独立的多个收购方是否存在隐性关联关系?"拆分式"易主背后是否为"分仓式"减持铺路?提 前"抢跑"的股价是否暗藏内幕交易风险?公司过往财报疑团会否随着易主而石沉大海?若方案最终实 施,其他公司会否群起效仿? 同时,交易完成后,安吉以清的控股比例并不高,仅三只信托及私募产品的合计持股就足以动摇安吉以 清对上市公司的控制权,更遑论原实控人丁福如方还保留大额持股。 如果没有足够的控制方式与安全保障,安吉以清及其背后的金亚伟怎敢入局收购? 更耐人寻 ...